Related Experiment Video
Updated: Aug 30, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Dual Targeting Anti-Osteoporotic Therapy Through Potential Nanotherapeutic Approaches
Sagar Salave1, Dhwani Rana1, Derajram Benival1
1Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, India.
Abstract:
Osteoporosis is characterised by a major public health burden, particularly taking into account the ageing global population. Therapeutic modalities for osteoporosis are categorised on the basis of their effect on bone remodeling: antiresorptive and anabolic agents. Anabolic drugs are favoured as they promote the formation of new bone, whereas antiresorptive drugs terminate the further deterioration of bone. Non-specific delivery of anabolic agents results in prolonged kidney exposure causing malignant hypercalcemia, whereas antiresorptive agents and bisphosphonates may produce osteonecrosis of the jaw. Several clinical trials have been reported for combinational therapy of anabolic agents and antiresorptive agents for osteoporosis. However, none of them have proven their cumulative effects in the treatment of disease. The present work emphasizes a dualtargeting drug delivery approach comprising of bone anabolic and antiresorptive agents that would simultaneously deliver the therapeutic agents to both the zones of bone. The anticipated pioneering delivery approach will intensify the explicit interaction between the therapeutic agent and bone surfaces separately without developing severe adverse effects and improve osteoporotic therapy effectively compared to non-targeted drug delivery.
Insights
This study introduces a dual-targeting drug delivery system for osteoporosis, combining anabolic and antiresorptive agents. This approach aims to improve bone formation and reduce bone loss effectively while minimizing side effects.
Area of Science:
- Biomedical Engineering
- Pharmacology
- Orthopedics
Background:
- Osteoporosis poses a significant public health challenge, especially with an aging global population.
- Current osteoporosis treatments include anabolic agents (promoting bone formation) and antiresorptive agents (inhibiting bone deterioration).
- Non-specific drug delivery can lead to severe side effects like hypercalcemia and osteonecrosis of the jaw.
Purpose of the Study:
- To develop a dual-targeting drug delivery system for osteoporosis.
- To simultaneously deliver anabolic and antiresorptive agents to specific bone zones.
- To enhance therapeutic effectiveness and reduce adverse effects compared to non-targeted delivery.
Main Methods:
- Designing a novel dual-targeting drug delivery approach.
- Incorporating both bone anabolic and antiresorptive agents into the delivery system.
- Evaluating the simultaneous delivery to distinct bone regions.
Main Results:
- The dual-targeting approach aims to deliver therapeutic agents to specific bone zones simultaneously.
- This method is anticipated to increase direct interaction between agents and bone surfaces.
- The approach is expected to improve osteoporosis therapy efficacy and safety.
Conclusions:
- A dual-targeting drug delivery system offers a promising strategy for osteoporosis treatment.
- Simultaneous delivery of anabolic and antiresorptive agents can potentially overcome limitations of current therapies.
- This innovative approach may lead to more effective and safer osteoporosis management.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:15Drugs that Stabilize Microtubules